Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com
Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call…
12,687$
5,64%
Echtzeit-Aktienkurs Syndax Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Syndax Pharmaceuticals Inc. Aktie
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an…
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
…
Syndax Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
…
Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance By Investing.com
Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance…
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript
…
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.…
Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials By Investing.com
Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials…
Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
…